Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’

Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease

AbbVie to acquire Capstan Therapeutics for $2.1 billion

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo

Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration

BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types

Shin-Etsu Chemical and Hokkaido University develop lipid nanoparticle production system capable of both small-batch, high-mix production

Hyderabad based CSIR institutes playing pivotal role in drug discovery and genetic diagnostics: Dr. Jitendra Singh

In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025

Lonza implements streamlined operating model

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy

Croda opens advanced lipids manufacturing facility in Pennsylvania

This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner

Moderna announces updates on pandemic influenza program

The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines

Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery

Increases speed to market for drug developers working on nucleic acid therapeutics